- Home
- HALO
as 06-20-2025 4:00pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.4B | IPO Year: | N/A |
| Target Price: | $63.56 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.76 | EPS Growth: | 55.40 |
| 52 Week Low/High: | $42.01 - $70.50 | Next Earning Date: | 08-05-2025 |
| Revenue: | $1,084,306,000 | Revenue Growth: | 25.64% |
| Revenue Growth (this year): | 25.77% | Revenue Growth (next year): | 18.01% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Henderson Jeffrey William | HALO | Director | Apr 28 '25 | Sell | $60.67 | 4,497 | $271,467.09 | 28,811 | |
| Henderson Jeffrey William | HALO | Director | Apr 1 '25 | Sell | $64.05 | 503 | $32,217.15 | 28,811 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Zacks
5 days ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Zacks
8 days ago
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Zacks
9 days ago
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
Argus Research
10 days ago
HALO: What does Argus have to say about HALO?
Zacks
16 days ago
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
TipRanks
17 days ago
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
TipRanks
17 days ago
Merck granted review of Halozyme patent claims by PTAB
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.